Nasopharyngeal carcinoma is a distinctive malignancy arising from the epithelium lining the nasopharynx, the space behind the nose and above the throat. Its geographic distribution is strikingly uneven: while rare in most of Europe and North America, it is endemic in Guangdong province, Hong Kong, and much of Southeast Asia, a pattern linked to Epstein-Barr virus infection, genetic susceptibility, and dietary factors such as salt-cured fish. Decades of progress in diagnostic imaging, intensity-modulated radiotherapy, and systemic chemotherapy have pushed five-year overall survival above 70 percent, transforming the clinical challenge. Yet survivors who beat their primary tumor remain at elevated risk of dying from recurrent disease, secondary cancers, cardiovascular complications of radiotherapy, and pulmonary illness, and until now there has been no established intervention specifically aimed at improving long-term survivorship in this growing population.

The new study, known as the Hong Kong NPC Survivor Study, screened 18,135 patients diagnosed with nasopharyngeal carcinoma between 1997 and 2015 and focused on 7,872 people who survived at least five years after diagnosis, the point at which most treatment-related mortality has subsided. Within this cohort, 2,439 patients had filled prescriptions totaling at least 90 days of statin therapy, while 5,433 had no record of statin use. The researchers drew their data from the Clinical Data Analysis Reporting System, a territory-wide electronic database maintained by Hong Kong’s Hospital Authority that captures more than 90 percent of the region’s cancer services across a population of 7.3 million, including demographics, diagnoses, prescriptions, laboratory results, and coded causes of death.

The headline result was dramatic. Statin users showed markedly better overall survival than non-users, with a hazard ratio of 0.46 in multivariable models, corresponding to roughly a 54 percent reduction in the risk of death from any cause. At ten years after diagnosis, 89.1 percent of statin users were alive compared with 71.8 percent of non-users; at fifteen years the figures were 77.2 percent versus 55.1 percent, and at twenty years 59.2 percent versus 42.4 percent. Because statin users in the raw cohort were older and carried more cardiovascular comorbidities such as diabetes, hypertension, and dyslipidemia, the team applied inverse probability of treatment weighting, a statistical technique that reweights the comparison groups to mimic randomization. After weighting, the apparent benefit grew even stronger, with hazard ratios of 0.39 under both the average treatment effect and average treatment effect on the treated frameworks.

Observational studies of this kind are notoriously vulnerable to immortal time bias, the artifact that arises when patients must survive long enough to receive a treatment before being counted as treated. The investigators confronted this problem head-on by modeling statin exposure as a time-varying covariate, so that each patient contributed unexposed person-time until they actually began taking the drug. Under this more conservative analysis the hazard ratio settled at 0.71, still a highly significant 29 percent reduction in mortality, and the authors candidly note that the unadjusted estimates likely overstate the true effect. They also performed a target trial emulation, a design that mimics the structure of a randomized trial by matching 1,332 statin initiators to non-initiators on age, sex, smoking, alcohol use, and baseline eligibility, and again found a significant protective effect with a hazard ratio of 0.54. Sensitivity analyses excluding patients with early recurrence or metastasis, and a landmark analysis resetting time zero at five years post-diagnosis, produced consistent results.

Perhaps the most intriguing findings concern why statin users died less often. Among the 2,773 deaths in the cohort, statin users had significantly lower risks of death from secondary primary malignancies, a hazard ratio of 0.51 after weighting, from cardiovascular disease, from pulmonary disease, and, in multivariable models, from recurrence or progression of the original cancer. This pattern suggests the drugs may be doing more than protecting the heart. Statins block HMG-CoA reductase, the rate-limiting enzyme of the mevalonate pathway, which supplies cancer cells with essential lipid intermediates for membrane synthesis and protein prenylation. Beyond this, laboratory work has documented anti-inflammatory, antioxidant, anti-angiogenic, and immune-modulatory properties, and statins have been shown to enhance chemotherapy efficacy and reduce radiation-induced vascular injury in nasopharyngeal carcinoma specifically. The reduced mortality from secondary cancers and recurrence hints that suppressing the mevalonate pathway may inhibit both new carcinogenesis and the outgrowth of residual tumor cells.

The benefit was strongly duration-dependent. Compared with short-term use of three months to two years, the risk of death fell by 30 percent with two to four years of statin therapy, by 45 percent with four to six years, and by 69 percent with more than six years of use. Notably, whether patients started statins during concurrent chemoradiotherapy or only after completing it made no significant difference to survival, implying that sustained exposure matters more than timing. This duration-response relationship fits a cytostatic rather than cytotoxic model of action: unlike chemotherapy, which rapidly shrinks tumors, statins may hold dormant disease in check over years, an effect that only accumulates with prolonged use. Parallel findings in prostate and breast cancer cohorts, where multi-year statin use was likewise associated with the largest mortality reductions, support this interpretation.

The type of statin also appeared to matter. All statin classes were associated with lower mortality, but the strongest signals came from atorvastatin and rosuvastatin, second- and third-generation agents with longer half-lives and higher affinity for HMG-CoA reductase, with hazard ratios of 0.35 and 0.30 respectively. Compared with first-generation drugs such as simvastatin and pravastatin, second-generation agents cut mortality risk by about a third and third-generation agents by more than half. Interestingly, the researchers found no clear advantage of lipophilic over hydrophilic statins, contrary to some prior laboratory evidence, suggesting that lipid-lowering potency and favorable pharmacokinetics may be more important than membrane penetration alone. In a telling negative control, statin users actually showed a higher risk of death from mental and neural disorders, a biologically unrelated endpoint; if the entire survival benefit were an artifact of healthy-user bias, statins would have appeared protective across the board.

The authors are careful to frame these results as hypothesis-generating rather than practice-changing. The retrospective design cannot exclude residual confounding by unmeasured factors such as lipid levels, body mass index, diet, and physical activity, and excluding patients who died within five years may have selectively enriched the cohort for indolent disease. Previous randomized trials of statin add-on therapy in patients with advanced cancer and poor prognosis showed no survival benefit, and a meta-analysis of 60 observational studies across cancer types found only a 22 percent reduction in cancer-specific mortality, far smaller than the signal reported here. Yet the Hong Kong cohort is by far the largest and longest-followed study in nasopharyngeal carcinoma, and its rigorous bias-control methods lend unusual credibility to the association.

The practical implications are considerable. Immunotherapy has recently demonstrated a 37 percent reduction in the risk of death in recurrent or metastatic nasopharyngeal carcinoma, but its cost places it far beyond most patients in the endemic regions of Southeast Asia and Southern China. Statins, by contrast, are generic, affordable, well tolerated, and carry a decades-long safety record. If prospective randomized trials confirm that sustained statin therapy improves long-term survival in cancer survivors, the drugs could offer an accessible adjunctive strategy for the thousands of patients who beat nasopharyngeal carcinoma each year but remain at lifelong risk, particularly in low- and middle-income countries where the burden of this virus-driven cancer is heaviest.

Subject of Research: The effect of statin use on long-term mortality among survivors of nasopharyngeal carcinoma

Article Title: Effect of statins on the mortality of long-term survivors of nasopharyngeal carcinoma: a population-based study in endemic area

Article References: Xu, R.-Y., Au, P. C.-M., Chan, K. S.-K., Cheung, C.-L., Fong, J. K.-S., Sing, C.-W., Chiu, M. K.-L., Chow, J. C.-H., Cheung, K. K.-M., Wong, E. C.-Y., Lau, T. T.-S., Chan, A. S.-Y., Wong, K. C.-W., Tin, W. W.-Y., Lee, V. H.-F., Lee, A. W.-M., Ng, W.-T., Wong, I. C.-K., & Chiang, C.-L. (2026). Effect of statins on the mortality of long-term survivors of nasopharyngeal carcinoma: a population-based study in endemic area. The Lancet Regional Health – Western Pacific, 75, Article 101993. https://doi.org/10.1016/j.lanwpc.2026.101993

Image Credits: AI Generated

DOI: 10.1016/j.lanwpc.2026.101993

Keywords: statins, nasopharyngeal carcinoma, cancer survivorship, Hong Kong cohort study, overall survival, mevalonate pathway, secondary primary malignancy, cardiovascular mortality, target trial emulation, immortal time bias, atorvastatin, rosuvastatin